Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial

BACKGROUND: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant FOLFOX-4 chemotherapy has become the standard of care. However, for 20 to 30 % of these patients, the current curative treatment strategy of surgical excision followed by adjuvant c...

Descripción completa

Detalles Bibliográficos
Autores principales: Karoui, Mehdi, Rullier, Anne, Luciani, Alain, Bonnetain, Franck, Auriault, Marie-Luce, Sarran, Antony, Monges, Geneviève, Trillaud, Hervé, Le Malicot, Karine, Leroy, Karen, Sobhani, Iradj, Bardier, Armelle, Moreau, Marie, Brindel, Isabelle, Seitz, Jean François, Taieb, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497499/
https://www.ncbi.nlm.nih.gov/pubmed/26156156
http://dx.doi.org/10.1186/s12885-015-1507-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497499/
https://www.ncbi.nlm.nih.gov/pubmed/26156156
http://dx.doi.org/10.1186/s12885-015-1507-3

Ejemplares similares